Software As A Medical Device (SaMD) For Respiratory Care Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Software As A Medical Device (SaMD) For Respiratory Care Market Trends and Insights

Rising Adoption of AI-Enabled Respiratory Decision Support

AI-enabled respiratory decision support is moving beyond pilots and into routine clinical procurement in the software as a medical device (SaMD) for respiratory care market. A randomized controlled trial published in 2024 showed that AI-assisted spirometry interpretation improved COPD diagnosis prediction among primary care clinicians, particularly in cases that clinicians might otherwise have missed. A 2025 blinded diagnostic accuracy study reported an area under the curve of 0.914 for AI spirometry software in a primary care dataset of 1,113 patients. In July 2026, Autonomous Healthcare received FDA De Novo marketing authorization for Syncron-E, creating a new device classification for ventilator waveform analysis software and supporting a clearer regulatory path for focused respiratory algorithms. Clinical validation and clearer review pathways are shortening commercialization timelines and attracting more capital and product development into the software as a medical device (SaMD) for respiratory care market.

Shift From Episodic to Continuous Home-Based Respiratory Monitoring

The shift from clinic-based checks to continuous home-based monitoring is reshaping product design and purchasing priorities across the software as a medical device (SaMD) for respiratory care market. Connected spirometers, inhalers, and wearables generate large patient data streams, while software converts these signals into alerts, trends, and care actions. This shift is one reason homecare settings are growing faster than other end-user categories, with a projected CAGR of 12.33% through 2031. In June 2026, PanopticAI received FDA 510(k) clearance for contactless respiratory rate measurement through a smartphone camera, reinforcing the move toward software subscriptions, monitoring intelligence, and scalable remote care workflows.

Expansion of Reimbursement-Ready Remote Patient Monitoring Workflows

The expansion of reimbursement-ready monitoring workflows is creating a practical route into routine care delivery for the software as a medical device (SaMD) for respiratory care market. The CY 2026 Medicare Physician Fee Schedule finalized new respiratory remote therapeutic monitoring coding changes, including CPT 98984 for 2 to 15 monitoring days in a 30-day period, lowering the billing threshold for respiratory monitoring activity. The policy also recognized software infrastructure, cloud storage, and cybersecurity as cost elements in remote monitoring economics. Existing respiratory RTM code structures continue to support monthly billing for device supply, helping providers invest in programs built on continuous software engagement rather than one-time device use.

Higher Clinical Demand for Exacerbation Prediction and Therapy Adherence

Clinical demand is rising for software that can predict exacerbations earlier and improve therapy adherence within the software as a medical device (SaMD) for respiratory care market. This is critical in chronic respiratory care, where poor inhaler use, missed therapy, and weak follow-up between visits contribute to avoidable deterioration. A 2025 study on an AI-powered smart inhaler showed that software can evaluate inhalation quality against clinical benchmarks instead of only recording actuation events. Therapy management reflects this demand most clearly and is projected to grow at a CAGR of 13.35% through 2031 as the market shifts toward more personalized intervention.

Regulatory Reclassification Risk for Signal-Processing Software

Regulatory classification remains a key uncertainty for parts of the software as a medical device (SaMD) for respiratory care market. A tool that starts as low-risk decision support can shift into a regulated device category once its outputs become more treatment-directed or clinically decisive. The FDA's December 2024 guidance on AI-enabled device software clarified that lifecycle controls, update plans, and performance documentation mattered throughout the product life of regulated software, not only at launch. In April 2026, Philips issued a Class I product correction related to Trilogy Evo ventilator software, affecting more than 113,700 devices globally and highlighting how software faults in respiratory care escalated into patient safety and recall issues. Across Europe, the Cyber Resilience Act added another layer of cybersecurity responsibility on top of medical device compliance, increasing cost and complexity for companies operating across multiple jurisdictions.

Weak Prospective Evidence and Reimbursement Fragmentation

Evidence quality remains uneven in the software as a medical device (SaMD) for respiratory care market, particularly when stakeholders assess products for large-scale reimbursement or national rollout. Many validation studies remain retrospective, single-site, or limited in patient mix, making it harder for payers to determine whether results will hold in broader clinical use. A 2025 audit of AI spirometry software found that sensitivity dropped by around 10% in non-White populations compared with all-White training cohorts, raising concerns about generalizability and equitable performance. Broader academic research on pulmonary AI also emphasized the need to improve equity, transparency, and representation across respiratory algorithms before large-scale adoption becomes routine. Reimbursement pathways outside the United States also remain less consistent, limiting global scaling for smaller developers that lack the resources to support multiple country-specific evidence and payment submissions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Software Dominates Revenue, Services Command the Growth Premium

Software held 69.55% of revenue in 2025, keeping it the core revenue engine in the software as a medical device (SaMD) for respiratory care market. This leadership reflected strong demand for diagnostic software, monitoring platforms, and decision support tools across institutional and home-based respiratory workflows. The software as a medical device (SaMD) for respiratory care market size for services is forecast to expand at a CAGR of 11.93% through 2031, placing services ahead of the broader category growth pace.

This faster growth showed that buyers were moving beyond software licenses and investing in deployment, validation, support, and managed service layers. Health systems increasingly required vendor support for integration, staff onboarding, and post-deployment monitoring. The shift also reflected the need for respiratory software to prove clinical performance over time, not only at the point of initial sale.

By Deployment Mode: Cloud Holds the Volume, On-Premises Captures the High-Acuity Niche

Cloud-based deployment held 64.22% of revenue in 2025, making it the largest deployment model in the software as a medical device (SaMD) for respiratory care market. Its lead came from centralized updates, easier storage expansion, cross-site access, and a simpler path to continuous algorithm improvement. The software as a medical device (SaMD) for respiratory care market share for cloud platforms stayed strong due to demand from homecare and ambulatory workflows.

On-premises deployment is projected to grow at a CAGR of 12.67% through 2031, making it the fastest-growing deployment mode despite the broader shift toward cloud architecture. This growth reflected demand from large hospital systems, intensive care settings, and organizations requiring stricter control over sensitive respiratory data. Some use cases required very low latency and uninterrupted processing, making local or tightly controlled private environments more practical for waveform-driven software such as ventilator analysis tools.

By Application: Diagnosis Anchors the Market, Therapy Management Reshapes the Growth Curve

Diagnosis and screening accounted for 47.66% of revenue in 2025, keeping it the largest application area in the software as a medical device (SaMD) for respiratory care market. The category grew around tools that helped clinicians identify obstructive airway disease earlier through AI-supported spirometry, acoustic analysis, and waveform interpretation. Evidence continued to support software use in improving diagnostic performance in primary care environments where respiratory expertise was not always available.

Therapy management is forecast to grow at a CAGR of 13.35% through 2031, making it the fastest-moving application in the software as a medical device (SaMD) for respiratory care market. This reflected stronger demand for software that moved beyond observation and guided therapy adjustment, personalization, or reinforcement between visits. ResMed received FDA clearance for Smart Comfort in December 2025, and the product became commercially available in the United States in 2026 as an AI-enabled tool that recommends personalized CPAP comfort settings.

By End User: Hospitals Anchor Scale, Homecare Defines the Growth Frontier

Hospitals and clinics held 52.33% revenue share in 2025, keeping them the largest end-user group in the software as a medical device (SaMD) for respiratory care market. These settings continued to control much of the purchasing process for diagnostic software, interoperability requirements, and formal clinical onboarding. They also remained the first point of adoption for tools that affected treatment pathways or required review by respiratory specialists and hospital IT teams.

Homecare settings are forecast to grow at a CAGR of 12.33% through 2031, making them the fastest-growing end-user segment in the software as a medical device (SaMD) for respiratory care market. Growth was driven by connected devices, reimbursement progress, and patient expectations for more support outside formal care episodes. Home-based respiratory software shifted from passive tracking to guided management, with greater focus on adherence coaching, trend review, and escalation support when symptoms worsened.

Geography Analysis

North America accounted for 42.25% of global revenue in 2025, maintaining its position as the largest regional bloc in the software as a medical device (SaMD) for respiratory care market. The region benefited from mature remote care infrastructure, established respiratory device usage, and a regulatory framework that continued to guide updates and oversight for AI-enabled medical software. Supportive reimbursement policies also improved adoption, especially for respiratory monitoring workflows with clearer coding routes and lower billing barriers. 

Europe remained a major region in the software as a medical device (SaMD) for respiratory care market, supported by strong public health systems and well-defined digital and regulatory standards. The European Health Data Space advanced interoperability and data exchange, supporting broader adoption of connected health software across member states. This gave respiratory software vendors clearer long-term direction on product integration with clinical systems. Europe’s stricter compliance, cybersecurity, and certification requirements benefited firms with the resources to manage regulatory and product operations across countries.

Asia-Pacific was the fastest-growing region, with the software as a medical device (SaMD) for respiratory care market size in the region projected to register a CAGR of 13.95% through 2031. High respiratory disease burden, rising digital health investment, and stronger commercialization of locally developed clinical software supported growth. In June 2026, Nozomi MedAlliance and Yamaguchi University began overseas commercialization work for an AI asthma individualized treatment platform, signaling a more outward-facing phase for Japanese respiratory SaMD development.